Neoadjuvant combo efficacious in high-risk prostate cancer

One-third of men with high-risk prostate cancer achieved pathologic complete response (pCR) or near-complete response to 6 months of preoperative therapy with abiraterone acetate (ZYTIGA), leuprolide, and prednisone, investigators reported at the American Society of Clinical Oncology annual meeting in Chicago.

Related Videos
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Blurred image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Jacob Taylor, MD, MPH, answers a question during a Zoom video interview
Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
Colin Goudelocke, MD, answers a question during a Zoom video interview
Laura Bukavina, MD, MPH, answers a question during a Zoom video interview
Related Content
© 2023 MJH Life Sciences

All rights reserved.